Plasma activity of of thrombin activatable fibrinolysis inhibitor in Crimean-Congo hemorrhagic fever

Sonmez, Mehmet; Aydin, Kemalettin; Durmus, Ahmet; Sucu, Nurgul; Yilmaz, Mustafa; Akdogan, Elif; Koksal, IFTAHAR; Ovali, Ercument; Omay, Serdar

doi:10.1016/j.jinf.2007.02.010

Plasma activity of of thrombin activatable fibrinolysis inhibitor in Crimean-Congo hemorrhagic fever

Sonmez M., Aydin K., Durmus A., Sucu N., Yilmaz M., Akdogan E., ...More

JOURNAL OF INFECTION, vol.55, no.2, pp.184-187, 2007 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 55 Issue: 2
Publication Date: 2007
Doi Number: 10.1016/j.jinf.2007.02.010
Journal Name: JOURNAL OF INFECTION
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.184-187
Keywords: thrombin activatable fibrinolysis inhibitor, Crimean-Congo hemorrhagic fever, VIRUS-INFECTION, PRIMATE MODELS, TAFI, EBOLA, COAGULATION
Acibadem Mehmet Ali Aydinlar University Affiliated: No

Abstract

Objectives: Crimean-Congo hemorrhagic fever (CCHF) is a potentially fatal viral infection. The exact mechanism for hemorrhage remains unknown. Thrombin activatable fibrinolysis inhibitor (TAFI) is a plasma procarboxypeptidase B-like proenzyme and synthesized in the liver, down-regulating fibrinolysis. In this study, we measured the TAR activity in plasma of patients with CCHF to examine the relationship between hemorrhage and the pathogenesis of CCHF.